Dendritic cell-based immunotherapy
TLDR
What has been learned thus far about human DC biology from clinical studies are discussed, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity are discussed.Abstract:
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.read more
Citations
More filters
Journal ArticleDOI
Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
TL;DR: The biological functions of immune cells within TME and their roles in cancer immunotherapy are reviewed, and the perspectives of the basic studies for improving the effectiveness of the clinical use are discussed.
Journal ArticleDOI
Therapeutic Targeting of the Tumor Microenvironment
TL;DR: A comprehensive analysis of the current therapies targeting the tumor microenvironment (TME) is provided in this paper, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.
Journal ArticleDOI
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
TL;DR: It is argued that in various contexts next-generation DC vaccines are ready to meet some challenges currently confronting ICIs, thereby raising the need to integrate DC vaccines in future combinatorial immunotherapy regimens.
Journal ArticleDOI
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
TL;DR: The role of the different immune landscapes in CRC and their relationships with defined CRC genetic subtypes are discussed and in which ways CRC cells develop mechanisms to resist ICI are considered.
Journal ArticleDOI
Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source
TL;DR: This review summarized the current knowledge on the application of EVs as DDS from the perspective of different cell origin and weighted the advantages and bottlenecks of EV-based DDS.
References
More filters
Journal Article
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma (vol 21, pg 81, 2015)
Carsten Linnemann,Marit M. van Buuren,Laura Bies,Els M. E. Verdegaal,Remko Schotte,Jorg J A Calis,Sam Behjati,Arno Velds,Henk Hilkmann,Dris El Atmioui,Marten Visser,Michael R. Stratton,John B. A. G. Haanen,Hergen Spits,Sjoerd H. van der Burg,Ton N. Schumacher +15 more
TL;DR: This work addressed whether neo-antigen–specific CD4+ T-cell reactivity is a common property in human melanoma.
Journal ArticleDOI
Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells.
Megan K. Levings,Silvia Gregori,Eleonora Tresoldi,Sabrina Cazzaniga,Chiara Bonini,Maria Grazia Roncarolo +5 more
TL;DR: A standardized and highly reproducible protocol to differentiate Tr cells by repetitive exposure of naive peripheral blood CD4(+) T cells to allogeneic iDCs is developed and can be used to generate large numbers of alloantigen-specific Tr1 cells for clinical use as a cellular therapy to restore peripheral tolerance.
Journal ArticleDOI
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le,Andrea Wang-Gillam,Vincent J. Picozzi,Tim F. Greten,Todd S. Crocenzi,Gregory M. Springett,Michael A. Morse,Herbert J. Zeh,Deirdre Jill Cohen,Robert L. Fine,Beth Onners,Jennifer N. Uram,Daniel A. Laheru,Eric R. Lutz,Sara Solt,Aimee Murphy,Justin Skoble,Ed Lemmens,John Grous,Thomas W. Dubensky,Dirk G. Brockstedt,Elizabeth M. Jaffee +21 more
TL;DR: Heterologous prime/boost vaccination with Cy/GVAX and CRS-207 extended survival for patients with pancreatic cancer, with minimal toxicity.
Journal ArticleDOI
Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
M V Dhodapkar,Ralph M. Steinman,Mark Sapp,H Desai,C Fossella,Joseph Krasovsky,Sean M. Donahoe,P R Dunbar,Vincenzo Cerundolo,Douglas F. Nixon,Nina Bhardwaj +10 more
TL;DR: These data provide the first controlled evidence of the immunogenicity of DCs in humans, and demonstrate that a single injection of mature DCs rapidly expands T-cell immunity.
Journal ArticleDOI
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Joshua Brody,Weiyun Z. Ai,Debra K. Czerwinski,James A. Torchia,Mia A. Levy,Ranjana H. Advani,Youn H. Kim,Richard T. Hoppe,Susan J. Knox,Lewis K. Shin,Irene Wapnir,Robert Tibshirani,Ronald Levy +12 more
TL;DR: In situ tumor vaccination with a TLR9 agonist induces systemic antilymphoma clinical responses and is clinically feasible and does not require the production of a customized vaccine product.
Related Papers (5)
Dendritic cells and the control of immunity
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more